Seems like a promisinf start.

From the research journal - These results suggest potential benefit of BD2-selective apabetalone in controlling inflammation and oxidative stress in FD, which will be further investigated in clinical trials.

Too bad Rvx can't get the financing to keep this science rolling.

Toinv